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MRI-Targeted Biopsy for Prostate-Cancer Diagnosis
To the Editor: In PRECISION (Prostate Evalua-
tion for Clinically Important Disease: Sampling 
Using Image Guidance or Not?), a multicenter, 
randomized, noninferiority trial, Kasivisvanathan 
et al. (May 10 issue)1 found that magnetic reso-
nance imaging (MRI)–targeted biopsy was superior 
to standard transrectal ultrasonography–guided 
biopsy in men at risk for prostate cancer who had 
not undergone biopsy previously. Of the 246 pa-
tients in the MRI-targeted biopsy group, 62 (25.2%) 
underwent MRI performed with the use of a 1.5-T 
scanner and 175 (71.1%) had lesion scores of 3 or 
greater (combined results from 1.5-T and 3.0-T 
scanners) according to the Prostate Imaging–
Reporting and Data System, version 2 (on a scale 
from 1 to 5, with higher numbers indicating a 
greater likelihood of clinically significant cancer). 
Eight centers had a 1.5-T MRI scanner, and only 
1 of them used an endorectal coil, whereas 15 
centers had a 3.0-T MRI scanner, and 2 of them 
used an endorectal coil. We think it would be 
interesting to know how many of the lesions 
were detected by an MRI performed with a 1.5-T 
scanner.
In addition, it could be worthwhile to perform 
sensitivity analyses to exclude any difference 
attributable to varying magnetic field strengths. 
Such analyses (one possibly with an endorectal 
coil and one without an endorectal coil, if num-
bers allow that) could also confirm the equiva-
lence of both magnet strengths to detect clini-
cally significant cancer.
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To the Editor: Urologists have been performing 
transrectal ultrasonography–guided prostate bi-
opsies for decades. The results of the PRECISION 
trial suggest that urologists have not been detect-
ing large numbers of the most aggressive cancers. 
These cancers are graded according to the Glea-
son score, which is composed of a primary (most 
predominant) grade plus a secondary (highest 
nonpredominant) grade; the range for a primary 
or secondary grade is from 3 to 5, with the Glea-
son sum ranging from 6 to 10, and with higher 
scores indicating a more aggressive form of pros-
tate cancer. The annual incidence of prostate 
cancer in the United States is 165,000 cases,1 and 
approximately 50% of biopsies to detect prostate 
cancer are positive. Thus, in the PRECISION trial, 
an absolute risk difference of 5.5 percentage 
points between the MRI-targeted biopsy group 
and the standard-biopsy group for cancers of 
Gleason sum 8 to 10 suggests that urologists 
have been missing approximately 20,000 such 
cancers every year for decades.
So where are all the bodies? If transrectal 
ultrasonography–guided biopsy missed so many 
of the worst cancers, we would expect that it 
would be routine for patients in our clinics to 
present with metastatic disease a few years after 
a negative biopsy. But such cases are extremely 
rare. In a Danish Cancer Registry study based on 
data from men with negative biopsy results and 
a prostate-specific–antigen level of less than 10 ng 
per milliliter (the level in the majority of partici-
pants in the PRECISION trial), the cumulative 
incidence of prostate cancer–specific death was 
0.7% at 15 years.2
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The authors reply: We agree with Martini et al. 
that it is useful to know the differences in the 
performance of 1.5-T and 3.0-T MRI machines. 
We allowed both coil strengths as part of the 
pragmatic trial design. Of note, we did not power 
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the trial to assess for differences in clinically sig-
nificant cancer in the subgroups with different 
coil strengths. Eighteen of 62 men in the 1.5-T 
MRI group (29%; 95% confidence interval [CI], 
19 to 41) and 75 of 184 men in the 3.0-T MRI 
group (41%; 95% CI, 34 to 48) had clinically sig-
nificant cancer. Since men were not randomly 
assigned to undergo MRI performed with 1.5-T 
or 3.0-T scanners, the differences observed may 
be confounded by other factors. The Prostate MRI 
Imaging Study (PROMIS), a multicenter study in-
volving 576 men, used only 1.5-T MRI machines 
and showed that MRI was superior to transrectal 
ultrasonography–guided prostate biopsy for the 
detection of clinically significant cancer.1
We agree with Vickers and Ehdaie that urolo-
gists have been performing transrectal ultraso-
nography–guided biopsies for decades, but we 
would assert that tradition alone is an insuffi-
cient reason not to change practice in the face of 
growing scientific evidence. Transrectal ultraso-
nography–guided biopsy has been shown to miss 
more than 50% of clinically significant cancers 
in men.1 Many men undergo repeat transrectal 
ultrasonography–guided biopsy, with a 2 to 4% 
risk of sepsis and costs to health services.2 The 
Danish Cancer Registry study cited by Vickers 
et al. showed that in 17% of men with negative 
results on transrectal ultrasonography–guided bi-
opsy who underwent repeat biopsy, prostate can-
cer of Gleason sum 8 was missed.3 This is unde-
sirable for a diagnostic test. In the PRECISION 
trial, with the use of the same threshold for 
clinically significant cancers as described by 
Vickers et al., MRI with or without targeted bi-
opsy detected 6% (95% CI, 1 to 10) more cancers 
of Gleason sum 8 or worse than transrectal ultra-
sonography–guided biopsy. In addition, 13% 
(95% CI, 7 to 19) fewer men in the MRI-targeted 
biopsy group than in the standard-biopsy group 
received a diagnosis of clinically insignificant 
cancer — a diagnosis that can lead to consider-
able overtreatment and harm to men. Other 
studies have also shown that MRI-targeted biopsy 
detects more clinically significant cancer and less 
clinically insignificant cancer than transrectal 
ultrasonography–guided biopsy.4 We acknowledge 
that there is uncertainty as to the prognosis of 
clinically significant cancer identified by MRI-
targeted biopsy,5 although future studies, and 
not conjecture, may ascertain the risk of death 
among these patients.
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Single-Inhaler Triple versus Dual Therapy in Patients with COPD
To the Editor: In the randomized Informing 
the Pathway of COPD Treatment (IMPACT) trial 
involving more than 10,000 patients with chronic 
obstructive pulmonary disease (COPD), Lipson 
and colleagues (May 3 issue)1 compared a once-
daily combination of f luticasone furoate (an 
 inhaled glucocorticoid), umeclidinium (a long-
acting muscarinic antagonist [LAMA]), and vilan-
terol (a long-acting β2-agonist [LABA]) with an 
inhaled glucocorticoid–LABA or a LABA–LAMA 
combination. The primary outcome was the 
 annual rate of moderate or severe COPD exacer-
bations. Since a large fraction of COPD exacerba-
tions are infectious in origin,2 we wonder whether 
there were any differences among the three groups 
with respect to the proportion of patients who 
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